Examinant per Autoria "Rodriguez-Vida, Alejo"
Resultats per pàgina
Opcions d'ordenació
Ítem Accés Obert Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients(Wiley, 2023) Córdoba Sánchez, Julián; Picola, Natàlia; Rodriguez-Vida, Alejo; Costa, Marc; Marmolejo Castañeda, David; Pérez Márquez, Meritxell; Muñoz Rodriguez, Jesús; Gaya Sopena, Josep Maria; Bravo, Alejandra; Buisan, Oscar; Servian, Pol; Suárez Novo, José Francisco; Musquera Felip, Mireia; Ribal, María José; Alcaraz Asensio, Antonio; Vilaseca, Antoni
Ítem Accés Obert Association of tumor mutational burden and PD-L1 with the efficacy of pembrolizumab with or without chemotherapy versus chemotherapy in advanced urothelial carcinoma(American Association for Cancer Research (AACR), 2024) Fléchon, Aude; Rodriguez-Vida, Alejo; Matsubara, Nobuaki
Ítem Accés Obert Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors(Wiley, 2024) Robbrecht, Debbie; Rodriguez-Vida, Alejo; Wang, Rui
Ítem Accés Obert Cell plasticity-related phenotypes and taxanes resistance in castration-resistant prostate cáncer(Frontiers, 2020) Jiménez, Natalia; Reig, Òscar; Montalbo, Ruth; Milà-Guasch, Maria; Nadal-Dieste, Lluis; Castellano, Giancarlo; Lozano, Juan José; Victoria, Iván; Font, Albert; Rodriguez-Vida, Alejo; Carles, Joan; Suárez, Cristina; Doménech, Montserrat; Sala-González, Núria; Fernández, Pedro Luís; Rodríguez-Carunchio, Leonardo; Díaz, Sherley; Prat, Aleix; Marín-Aguilera, Mercedes; Mellado, Begoña
Ítem Accés Obert Complexity of FGFR signalling in metastatic urothelial cancer.(BioMed Central, 2015) Rodriguez-Vida, Alejo; Saggese, Matilde; Hughes, Simon; Rudman, Sarah; Chowdhury, Simon; Smith, Neil R.; Lawrence, Peter; Rooney, Claire; Dougherty, Brian; Landers, Donal; Kilgour, Elaine; Arkenau, Hendrik-Tobias
Ítem Accés Obert Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients(Elsevier, 2024) Jiménez, Natalia; Rodriguez-Vida, Alejo; Mellado, Begoña
Ítem Accés Obert Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis(Wiley, 2023) Del Carpio, Luis P.; Algarra, María Asunción; Sabaté-Llobera, Aida; Rodriguez-Vida, Alejo; Rossi-Seoane, Susana; Ruiz, Sandra; Leiva, David; Ramos, Emilio; Lladò, Laura; Lorenzo, Daniel; Gutiérrez, Cristina; Cortes-Romera, Montserrat; Caminal, Josep Maria; Piulats, Josep Maria
Ítem Accés Obert Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)(BioMed Central, 2021) Grivas, Petros; Rodriguez-Vida, Alejo; Chowdhury, Simon
Ítem Accés Obert Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial(Springer, 2024) Climent, Miguel Ángel; Álvarez, Carlos; Morales-Barrera, Rafael; Maroto, Pablo; Rodriguez-Vida, Alejo; Méndez-Vidal, María José; García del Muro, Xavier; Puente, Javier; Láinez, Nuria; Vázquez, Sergio; Castellano, Daniel; Gómez Lang, Carmen; Wang, Jing; Di Pietro, Alessandra; Davis, Craig; Sanz Castillo, Belén; Bolós, M. Victoria; Valderrama, Begoña P.
Ítem Accés Obert Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non-muscle-invasive bladder cancer(American Association for Cancer Research (AACR), 2020) Bellmunt Molins, Joaquim, 1959-; Perera Bel, Júlia; Orsola, Anna; Rodriguez-Vida, Alejo; Juanpere, Nuria; Lloreta, Josep, 1958-; Hernández, Silvia; Kwiatkowski, David J.
Ítem Accés Obert Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer(Springer, 2024) Segalés Tañà, Laura, 1994-; Juanpere, Nuria; Gallarín, Nerea; Lorenzo Perez, Marta; López Martos, David; Perera Bel, Júlia; Rodriguez-Vida, Alejo; Fumadó Ciutat, Lluis; Cecchini Rosell, Lluís; Bellmunt Molins, Joaquim, 1959-; Lloreta, Josep, 1958-; Hernández Llodrà, Silvia
Ítem Accés Obert Impact of new systemic therapies in overall survival in non-metastatic castration resistant prostate cancer: systematic review and meta-analysis(Elsevier, 2022) Rodriguez-Vida, Alejo; Rodríguez-Alonso, Andrés; Useros-Rodríguez, Eduardo; Lopez-Campos, Fernando; Amor-Carro, Oscar; Arribas-Ruiz, Alberto; Martínez-Torres, Javier; Roca-Pardiñas, Javier; Quesada-García, Alba; Muñoz-Del-Toro, Jacobo R.; Juárez-Soto, Álvaro
Ítem Accés Obert Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study(Elsevier, 2024) Rodriguez-Vida, Alejo; Valderrama, Begoña P.; Castellano, Daniel; Pinto, Álvaro; Mellado, Begoña; Puente, Javier; Climent, Miguel Ángel; Doménech, Montserrat; Vazquez, Federico; Perez-Gracia, Jose Luis; Bonfill, Teresa; Morales-Barrera, Rafael; González-Billalabeitia, Enrique; Garcia-del-Muro, Xavier; Maroto, Pablo; Navarro-Gorro, Nil; Juanpere, Nuria; Juan, Oscar; Bellmunt Molins, Joaquim, 1959-
Ítem Accés Obert Metastatic calcinosis cutis secondary to selective fibroblast growth factor receptor inhibitor: rapid and complete regression after blood phosphate normalization and drug withdrawal(Society for Publication of Acta Dermato-Venereologica, 2020) López-Castillo, Daniel; March-Rodríguez, Alvaro; Rodriguez-Vida, Alejo; Pujol Vallverdú, Ramon Maria; Segura Tigell, Sonia
Ítem Accés Obert New treatment options for metastatic renal cell carcinoma(BMJ Publishing Group, 2017) Hutson, Thomas E.; Bellmunt Molins, Joaquim, 1959-; Strijbos, Michiel H.; Rodriguez-Vida, Alejo
Ítem Accés Obert Novel oral mTORC1/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Kα inhibitor TAK-117 in preclinical bladder cancer models(American Association for Cancer Research (AACR), 2019) Hernández Prat, Anna, 1984-; Rodriguez-Vida, Alejo; Juanpere, Nuria; Arpí Llucià, Oriol; Menéndez, Silvia; Soria-Jiménez, Luis; Martínez, Alejandro; Iarchouk, Natalia; Rojo, Federico; Albanell Mestres, Joan; Brake, Rachael; Rovira Guerín, Ana; Bellmunt Molins, Joaquim, 1959-
Ítem Accés Obert Pharmacokinetics (PK) of tiragolumab in first-in-human study in patients with mixed solid tumors (GO30103)(Wiley, 2024) Garralda, Elena; Oh, Do Youn; Italiano, Antoine; Bedard, Philippe L.; Delord, Jean-Pierre; Calvo, Emiliano; LoRusso, Patricia; Wainberg, Zev A.; Cervantes, Andrés; Rodriguez-Vida, Alejo; Shemesh, Colby S.; Sane, Rucha; Mendus, Diana; Ding, Hao; Hendricks, Robert; Meng, Ray; Cho, Byoung Chul; Kim, Tae Won; Wu, Benjamin
Ítem Accés Obert Plasma androgen receptor and docetaxel for metastatic castration-resistant prostate cancer(Elsevier, 2019) Conteduca, Vincenza; Rodriguez-Vida, Alejo; De Giorgi, Ugo
Ítem Accés Obert Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma(BMJ Publishing Group, 2017) Rodriguez-Vida, Alejo; Strijbos, Michiel H.; Hutson, Thomas Xavier
Ítem Embargament Prognostic value of PARP1 and PARP2 copy number alterations in prostate cancer(Elsevier, 2025) Segalés Tañà, Laura, 1994-; Bellmunt Molins, Joaquim, 1959-; Perera Bel, Júlia; Vargas-Parra, Gardenia; Juanpere, Nuria; Lopez-Segura, David; Rodriguez-Vida, Alejo; Colomo Saperas, Luis Alberto; Cecchini Rosell, Lluís; Lloreta, Josep, 1958-; Yélamos López, José; Fumadó Ciutat, Lluis; Hernández Llodrà, Silvia